var data={"title":"Pharmacology, dosing, and adverse effects of leflunomide in the treatment of rheumatoid arthritis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Pharmacology, dosing, and adverse effects of leflunomide in the treatment of rheumatoid arthritis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/contributors\" class=\"contributor contributor_credentials\">Robert Fox, MD, PhD</a></dd><dd><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/contributors\" class=\"contributor contributor_credentials\">Simon M Helfgott, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/contributors\" class=\"contributor contributor_credentials\">Ravinder N Maini, BA, MB BChir, FRCP, FMedSci, FRS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/contributors\" class=\"contributor contributor_credentials\">Paul L Romain, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Mar 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 01, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=leflunomide-drug-information\" class=\"drug drug_general\">Leflunomide</a> (LEF) is an isoxazole derivative used for the treatment of rheumatoid arthritis (RA). LEF, which inhibits pyrimidine synthesis, is structurally unrelated to other immunomodulatory disease-modifying antirheumatic drugs (DMARDs), exhibiting a distinct mechanism of action compared with other DMARDs used to treat RA.</p><p>The mechanism of action, pharmacology, dosing, and adverse effects of LEF, particularly in the context of its use in RA, will be reviewed here. The general approach to the management of RA and the use of LEF in the treatment of active disease are presented separately. (See <a href=\"topic.htm?path=general-principles-of-management-of-rheumatoid-arthritis-in-adults\" class=\"medical medical_review\">&quot;General principles of management of rheumatoid arthritis in adults&quot;</a> and <a href=\"topic.htm?path=alternatives-to-methotrexate-for-the-initial-treatment-of-rheumatoid-arthritis-in-adults\" class=\"medical medical_review\">&quot;Alternatives to methotrexate for the initial treatment of rheumatoid arthritis in adults&quot;</a> and <a href=\"topic.htm?path=treatment-of-rheumatoid-arthritis-in-adults-resistant-to-initial-nonbiologic-dmard-therapy\" class=\"medical medical_review\">&quot;Treatment of rheumatoid arthritis in adults resistant to initial nonbiologic DMARD therapy&quot;</a> and <a href=\"topic.htm?path=treatment-of-rheumatoid-arthritis-in-adults-resistant-to-initial-biologic-dmard-therapy\" class=\"medical medical_review\">&quot;Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy&quot;</a>.)</p><p>The use of LEF in other conditions, including psoriatic arthritis, juvenile idiopathic arthritis, dermatomyositis, and systemic lupus erythematosus, and the use of <a href=\"topic.htm?path=teriflunomide-drug-information\" class=\"drug drug_general\">teriflunomide</a>, its active metabolite, in multiple sclerosis are discussed separately. (See <a href=\"topic.htm?path=treatment-of-psoriatic-arthritis#H69794688\" class=\"medical medical_review\">&quot;Treatment of psoriatic arthritis&quot;, section on 'Leflunomide'</a> and <a href=\"topic.htm?path=polyarticular-juvenile-idiopathic-arthritis-treatment#H9391133\" class=\"medical medical_review\">&quot;Polyarticular juvenile idiopathic arthritis: Treatment&quot;, section on 'Leflunomide'</a> and <a href=\"topic.htm?path=musculoskeletal-manifestations-of-systemic-lupus-erythematosus#H4\" class=\"medical medical_review\">&quot;Musculoskeletal manifestations of systemic lupus erythematosus&quot;, section on 'Treatment'</a> and <a href=\"topic.htm?path=management-of-refractory-discoid-lupus-and-subacute-cutaneous-lupus#H14534301\" class=\"medical medical_review\">&quot;Management of refractory discoid lupus and subacute cutaneous lupus&quot;, section on 'Leflunomide'</a> and <a href=\"topic.htm?path=management-of-refractory-cutaneous-dermatomyositis-in-adults#H1085497323\" class=\"medical medical_review\">&quot;Management of refractory cutaneous dermatomyositis in adults&quot;, section on 'Other systemic medications'</a> and <a href=\"topic.htm?path=disease-modifying-treatment-of-relapsing-remitting-multiple-sclerosis-in-adults#H901157902\" class=\"medical medical_review\">&quot;Disease-modifying treatment of relapsing-remitting multiple sclerosis in adults&quot;, section on 'Teriflunomide'</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">MODE OF ACTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=leflunomide-drug-information\" class=\"drug drug_general\">Leflunomide</a> (LEF) is an oral drug that is rapidly absorbed from the gastrointestinal tract; it acts as an immunomodulatory and immunosuppressive agent largely through inhibition of pyrimidine synthesis [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/1,2\" class=\"abstract_t\">1,2</a>].</p><p class=\"headingAnchor\" id=\"H2501225977\"><span class=\"h2\">Inhibition of DHODH and rUMP synthesis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Once absorbed, LEF is converted to its active form, a malononitrilamide known as <a href=\"topic.htm?path=teriflunomide-drug-information\" class=\"drug drug_general\">teriflunomide</a> (<a href=\"image.htm?imageKey=RHEUM%2F56364\" class=\"graphic graphic_figure graphicRef56364 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/3\" class=\"abstract_t\">3</a>]. The major action of teriflunomide at the doses given for rheumatoid arthritis (RA) is inhibition of the synthesis of a pyrimidine known as ribonucleotide uridine monophosphate pyrimidine (rUMP).</p><p>LEF decreases the synthesis of rUMP through inhibition of the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH). Inhibition of DHODH leads to inability of activated cells to move from G1 to the S phase by activating the p52 pathways of apoptotic selection. Additional mechanisms of action have been noted, but the inhibition of rUMP is thought to be the primary mechanism involved at the levels of drug reached in most patients [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/4,5\" class=\"abstract_t\">4,5</a>].</p><p>The structure of the enzyme DHODH and the binding site for <a href=\"topic.htm?path=teriflunomide-drug-information\" class=\"drug drug_general\">teriflunomide</a> have been determined by x-ray crystallography [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/6\" class=\"abstract_t\">6</a>]. Human DHODH has two domains: an alpha-helical domain that forms the opening of a channel leading to the active site and an <span class=\"nowrap\">alpha/beta-barrel</span> domain that contains the active site. Teriflunomide binds within the channel of the alpha-helical domain to exert its inhibitory effect on the enzyme.</p><p class=\"headingAnchor\" id=\"H2301183157\"><span class=\"h2\">Effects on immune cells and inflammation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The inhibitory effects of LEF influence many components of the immune-inflammatory response, some of which may be relevant to its mode of action in RA [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/1,2\" class=\"abstract_t\">1,2</a>]. These include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Inhibition of leukocyte adhesion to vascular endothelial cells [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/7-14\" class=\"abstract_t\">7-14</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Preferential effects on self-reactive memory T cells [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/15\" class=\"abstract_t\">15</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Interference with dendritic cell function, disrupting antigen presentation</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Decreased synovial infiltration of lymphocytes and type I synoviocytes with reduced vascular inflammation and metalloproteinase production, perhaps decreasing radiographic progression [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/16,17\" class=\"abstract_t\">16,17</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Blocking two steps essential for nuclear factor (NF)-kappa B activation, including degradation of the inhibitor of kappa B alpha and the subsequent translocation of the p65 subunit to the nucleus, blocking the proinflammatory consequences of NF-kappa B activation [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/18\" class=\"abstract_t\">18</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Inhibition of the protein tyrosine kinases Janus kinase (Jak)1 and Jak3, which influence signaling through cytokine receptors [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/19,20\" class=\"abstract_t\">19,20</a>] and of mitogen-activated protein kinase kinase kinase 2 (MAP3K2) [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/20\" class=\"abstract_t\">20</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Decreasing the response to interleukin (IL)-4 by B cells [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/21-23\" class=\"abstract_t\">21-23</a>], inhibiting IL-10 and IL-11 secretion, and reducing IL-2 synthesis [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/24,25\" class=\"abstract_t\">24,25</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increasing synthesis of transforming growth factor (TGF)-beta [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/26\" class=\"abstract_t\">26</a>]</p><p/><p class=\"headingAnchor\" id=\"H470404786\"><span class=\"h2\">Genetic factors influencing effects of leflunomide</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>One study has suggested that polymorphisms in the estrogen receptor allele, estrogen receptor 1 (<em>ESR1</em>), may be associated with differences in efficacy among women treated with LEF [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/27\" class=\"abstract_t\">27</a>]. Another has suggested that a genetic polymorphism of <em>CYP1A2</em>, but not total or free <a href=\"topic.htm?path=teriflunomide-drug-information\" class=\"drug drug_general\">teriflunomide</a> concentrations, was associated with increased risk of discontinuing LEF due to side effects in patients with RA [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/28\" class=\"abstract_t\">28</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">PHARMACOKINETICS AND DRUG ELIMINATION</span></p><p class=\"headingAnchor\" id=\"H2709062733\"><span class=\"h2\">Pharmacokinetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=leflunomide-drug-information\" class=\"drug drug_general\">Leflunomide</a> (LEF) is well absorbed following oral administration. The serum half-life of <a href=\"topic.htm?path=teriflunomide-drug-information\" class=\"drug drug_general\">teriflunomide</a> is approximately 15 days, but the active metabolite, teriflunomide, undergoes extensive enterohepatic recirculation, and plasma levels of the active metabolite above 0.02 <span class=\"nowrap\">mg/L</span> may persist for up to two years.</p><p>Normally, drug elimination of <a href=\"topic.htm?path=teriflunomide-drug-information\" class=\"drug drug_general\">teriflunomide</a> is achieved through the kidneys and gastrointestinal tract in an approximately equal ratio [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/29\" class=\"abstract_t\">29</a>]. Teriflunomide is excreted in the urine as a glucuronide conjugate.</p><p>Studies in adults have not revealed differences in the pharmacokinetics of the drug based upon gender or age. However, clearance of LEF is increased 38 percent in smokers compared with nonsmokers [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/30\" class=\"abstract_t\">30</a>].</p><p class=\"headingAnchor\" id=\"H2803875512\"><span class=\"h2\">Drug metabolism and drug interactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The metabolic pathways used by LEF affect its interactions with other drugs:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">Warfarin</a> &ndash; LEF has been reported in some patients to potentiate the action of warfarin as a result of its mutual competition at the level of cytochrome metabolism [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/31,32\" class=\"abstract_t\">31,32</a>]. However, both increases and decreases in the effects of warfarin can be seen, and close monitoring is required in patients using both of these agents. (See <a href=\"#H4252372094\" class=\"local\">'Patients receiving vitamin K antagonists'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Other agents</strong> &ndash; Theoretically, LEF administration in patients with cytochrome 2C9 polymorphisms might alter levels of <a href=\"topic.htm?path=tolbutamide-drug-information\" class=\"drug drug_general\">tolbutamide</a>, <a href=\"topic.htm?path=glipizide-drug-information\" class=\"drug drug_general\">glipizide</a>, <a href=\"topic.htm?path=celecoxib-drug-information\" class=\"drug drug_general\">celecoxib</a>, and <a href=\"topic.htm?path=fluvastatin-drug-information\" class=\"drug drug_general\">fluvastatin</a> as it has been noted to cause such changes at higher levels in rodent models [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/33\" class=\"abstract_t\">33</a>].</p><p/><p class=\"headingAnchor\" id=\"H1540158001\"><span class=\"h2\">Treatment to accelerate drug elimination</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Accelerated elimination of the drug (eg, to prevent fetal risk during pregnancy due to potential drug exposure) can be achieved through the administration of <a href=\"topic.htm?path=cholestyramine-resin-drug-information\" class=\"drug drug_general\">cholestyramine</a> (8 g orally three times daily for 11 days) [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/4\" class=\"abstract_t\">4</a>]; this is effective because the drug's persistence depends upon enterohepatic circulation of the active metabolite. (See <a href=\"#H1257958\" class=\"local\">'Pregnancy and lactation'</a> below.)</p><p>This approach can be used if LEF is taken during pregnancy or if the patient becomes pregnant while taking LEF and if levels may persist from prior treatment.</p><p>Serum concentrations &lt;0.02 <span class=\"nowrap\">mg/L</span> should be verified by two separate tests performed at least 14 days apart. If serum concentrations are &gt;0.02 <span class=\"nowrap\">mg/L,</span> additional <a href=\"topic.htm?path=cholestyramine-resin-drug-information\" class=\"drug drug_general\">cholestyramine</a> treatment can be employed.</p><p>As an alternative to <a href=\"topic.htm?path=cholestyramine-resin-drug-information\" class=\"drug drug_general\">cholestyramine</a>, the Canadian labeling recommends that activated charcoal may be used to enhance drug elimination.</p><p class=\"headingAnchor\" id=\"H3746518806\"><span class=\"h1\">DOSING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=leflunomide-drug-information\" class=\"drug drug_general\">Leflunomide</a> (LEF) is taken once daily; a loading dose is sometimes used initially.</p><p class=\"headingAnchor\" id=\"H2124266280\"><span class=\"h2\">Role of loading dose</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A loading dose of 100 <span class=\"nowrap\">mg/day</span> for three days was used in some early clinical studies of LEF. However, use of a loading dose is associated with a higher likelihood of side effects, particularly diarrhea and other gastrointestinal disturbances. Thus, one of the authors (RF) and many experts prefer to begin LEF, starting at 20 mg per day, without a loading dose [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/34,35\" class=\"abstract_t\">34,35</a>]. The other author (SH) and some experts prefer to use a loading dose of 100 mg daily for the first three days at the start of therapy or once weekly for three weeks, while taking the regular daily dose on other days in an effort to more quickly reach a therapeutic effect.</p><p>There are very limited data available regarding the relative benefits and risks of a loading dose, although one randomized trial involving a total of 120 patients found no advantage to use of a loading dose (100 mg daily for three days) compared with initiating therapy at a fixed dose (20 mg daily), with adverse events occurring earlier in the loading-dose group [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/36\" class=\"abstract_t\">36</a>].</p><p class=\"headingAnchor\" id=\"H1339659498\"><span class=\"h2\">Ongoing daily dose</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The usual dose of LEF is 20 mg, administered orally, once daily, regardless of whether a loading dose was used. A 10 mg daily dose can be tried in patients with gastrointestinal intolerance of the usual dose, and the lower dose is sometimes used in patients treated with a combination of <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> (MTX) and LEF. (See <a href=\"topic.htm?path=treatment-of-rheumatoid-arthritis-in-adults-resistant-to-initial-nonbiologic-dmard-therapy#H47574172\" class=\"medical medical_review\">&quot;Treatment of rheumatoid arthritis in adults resistant to initial nonbiologic DMARD therapy&quot;, section on 'Leflunomide'</a>.)</p><p>Limited information is available concerning dosing in patients with renal or hepatic impairment. Results of single-dose studies in patients with chronic kidney disease indicate that LEF is not removed by continuous ambulatory peritoneal dialysis or by hemodialysis due to its high degree of protein binding [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/29,37\" class=\"abstract_t\">29,37</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">ADVERSE EFFECTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A range of potential adverse effects may occur in patients using <a href=\"topic.htm?path=leflunomide-drug-information\" class=\"drug drug_general\">leflunomide</a> (LEF); major concerns include hypertension, especially in patients on nonsteroidal antiinflammatory drugs (NSAIDs), diarrhea and nausea, hepatotoxicity, and risk of fetal and neonatal toxicity. The risks of LEF use during conception, pregnancy, and lactation are reviewed in detail separately. (See <a href=\"topic.htm?path=safety-of-antiinflammatory-and-immunosuppressive-drugs-in-rheumatic-diseases-during-pregnancy-and-lactation#H19\" class=\"medical medical_review\">&quot;Safety of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation&quot;, section on 'Leflunomide'</a>.)</p><p>The risk of adverse effects may be affected by specific gene polymorphisms. Observational studies indicate that cytochrome P450 (<em>CYP1A2</em>) and dihydroorotate dehydrogenase (<em>DHODH</em>) gene polymorphisms can influence the risk of adverse effects, but such testing is not available for routine clinical use [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/38,39\" class=\"abstract_t\">38,39</a>]. Adverse effects may also occur due to drug-drug interactions. (See <a href=\"#H2803875512\" class=\"local\">'Drug metabolism and drug interactions'</a> above.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Gastrointestinal</strong> &ndash; Diarrhea and nausea occur in 10 to 15 percent of patients taking LEF. These side effects are seldom severe enough to lead to drug discontinuation. Diarrhea may be more severe when a loading dose is used [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/34\" class=\"abstract_t\">34</a>]. Symptoms usually occur soon after starting therapy but may occur over time with chronic drug use.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hepatic</strong> &ndash; Threefold elevation of serum aminotransferases have been noted in up to 13 percent of patients treated with LEF [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/4,34\" class=\"abstract_t\">4,34</a>]. Careful monitoring of LEF has been thought to allow it to be used with a level of safety comparable with that of <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> (MTX) [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/40\" class=\"abstract_t\">40</a>]. (See <a href=\"#H3599805797\" class=\"local\">'Warnings and monitoring for liver disease'</a> below.)</p><p/><p class=\"bulletIndent1\">The changes in liver function are generally reversible with dose reduction or discontinuation of the drug. However, infrequently, hepatoxicity can be severe. Between August 2002 and May 2009, 49 cases of severe liver injury, including 14 cases of fatal liver failure, were reported to the US Food and Drug Administration (FDA) [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/41\" class=\"abstract_t\">41</a>].</p><p/><p class=\"bulletIndent1\">Most patients who experience transaminase elevation have one or more comorbidities that might contribute to hepatotoxicity, including concomitant NSAID or MTX therapy, previous or concurrent alcohol abuse, or viral or autoimmune hepatitis. The FDA issued a warning based upon these observations [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/41\" class=\"abstract_t\">41</a>]. Estimates of the risk of transaminase elevations vary:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In one practice-based study in Australia involving 2975 patients with rheumatoid arthritis (RA), the overall incidence of adverse effects was similar among patients receiving MTX alone, LEF alone, or a combination of the two agents [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/42\" class=\"abstract_t\">42</a>]. The frequency of patients with abnormal hepatic aminotransferases in these groups was 12, 16, and 19 percent, respectively.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Another study of a practice-based cohort of 1953 patients with RA and 151 with psoriatic arthritis found that the risks of elevated hepatic aminotransferase levels above the upper limit of normal were greater with the combination of LEF and MTX compared with monotherapy with either agent or with the use of neither agent (31 percent versus 17 to 22 percent versus 14 percent, respectively) [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/43\" class=\"abstract_t\">43</a>].</p><p/><p class=\"bulletIndent2\">Elevations of aminotransferase levels of greater than twice the upper limit of normal occurred in 1 to 2 percent of patients on LEF or MTX alone compared with 5 percent of patients on the combination. The risk appeared to be higher in patients with psoriatic arthritis and in those on higher doses of MTX.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hypertension</strong> &ndash; A small percentage of patients with RA develop hypertension when taking LEF [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/44,45\" class=\"abstract_t\">44,45</a>]. Concurrent therapy with NSAIDs is a risk factor. The proposed mechanism is the displacement of NSAIDs from albumin by <a href=\"topic.htm?path=teriflunomide-drug-information\" class=\"drug drug_general\">teriflunomide</a>, thereby increasing NSAID activity [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/45\" class=\"abstract_t\">45</a>]. Blood pressure monitoring is recommended during the first months of treatment and is also recommended if NSAID therapy is begun at a later date. (See <a href=\"topic.htm?path=nsaids-and-acetaminophen-effects-on-blood-pressure-and-hypertension\" class=\"medical medical_review\">&quot;NSAIDs and acetaminophen: Effects on blood pressure and hypertension&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Pulmonary</strong> &ndash; LEF treatment has been reported to be associated with an increased risk of interstitial lung disease. However, it is not clear whether this is a true effect or whether this is the result of &quot;channeling bias,&quot; in which patients with preexisting interstitial lung disease are more likely to be treated with LEF than MTX, which is known to cause this complication [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/46\" class=\"abstract_t\">46</a>]. A 2016 systematic review and meta-analysis of randomized trials failed to demonstrate increased pulmonary toxicity with LEF use [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/47\" class=\"abstract_t\">47</a>].</p><p/><p class=\"bulletIndent1\">We generally obtain a chest radiograph prior to therapy with LEF and avoid the use of LEF in patients with known interstitial lung disease or a history of MTX-induced lung toxicity. (See <a href=\"topic.htm?path=methotrexate-induced-lung-injury\" class=\"medical medical_review\">&quot;Methotrexate-induced lung injury&quot;</a> and <a href=\"topic.htm?path=drug-induced-lung-disease-in-rheumatoid-arthritis#H11\" class=\"medical medical_review\">&quot;Drug-induced lung disease in rheumatoid arthritis&quot;, section on 'Leflunomide'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Neurologic</strong> &ndash; Peripheral neuropathy has been reported in patients receiving LEF [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/48,49\" class=\"abstract_t\">48,49</a>], with partial improvement after drug removal with <a href=\"topic.htm?path=cholestyramine-resin-drug-information\" class=\"drug drug_general\">cholestyramine</a> [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/50\" class=\"abstract_t\">50</a>]. A review of 80 cases reported to the FDA noted that symptoms of peripheral nerve dysfunction, typically characterized by axonal polyneuropathy, began a mean of six months after beginning the drug [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/51\" class=\"abstract_t\">51</a>]. Discontinuation of LEF within 30 days of the onset of symptoms was associated with a better outcome than discontinuation at a later time. In another study, 5 of 50 RA patients treated with LEF developed symptoms of peripheral neuropathy, but all improved after stopping the drug [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/48\" class=\"abstract_t\">48</a>].</p><p/><p class=\"bulletIndent1\">Similarly, a case of aseptic meningitis that improved with drug removal has also been reported [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/52\" class=\"abstract_t\">52</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Dermatologic</strong> &ndash; Rash and alopecia occur in 10 to 15 percent of patients taking LEF. These side effects are typically mild and seldom lead to drug discontinuation.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hematologic</strong> &ndash; Leukopenia occurs very infrequently; estimates of incidence in patients taking LEF alone ranged from 1 in 3698 to 1 in 4582 patients exposed; for patients also taking MTX, the estimates ranged from 1 in 575 to 1 in 822 [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/29\" class=\"abstract_t\">29</a>]. Otherwise, hematologic toxicity primarily results from an interaction between LEF and other drugs. LEF may enhance the bone marrow toxicity of MTX, possibly leading to pancytopenia, agranulocytosis, or thrombocytopenia.</p><p/><p class=\"bulletIndent1\">LEF can potentiate the anticoagulant effect of <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/32\" class=\"abstract_t\">32</a>]. As a result, the international normalized ratio (INR) should be more carefully monitored after initiation of LEF in patients taking warfarin. (See <a href=\"topic.htm?path=warfarin-and-other-vkas-dosing-and-adverse-effects\" class=\"medical medical_review\">&quot;Warfarin and other VKAs: Dosing and adverse effects&quot;</a>.)</p><p/><p>In addition, there was a report in 2010, but not since, of contamination with commercial solvents during the manufacturing process in some generic preparations of LEF used in Asia [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/53\" class=\"abstract_t\">53</a>].</p><p class=\"headingAnchor\" id=\"H3691082048\"><span class=\"h1\">MONITORING</span></p><p class=\"headingAnchor\" id=\"H3681297272\"><span class=\"h2\">Routine laboratory monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In most patients, we obtain the following routine testing during treatment with <a href=\"topic.htm?path=leflunomide-drug-information\" class=\"drug drug_general\">leflunomide</a> (LEF): a complete blood count (CBC), aminotransferases, and creatinine every two to four weeks for the first three months or, after increasing the dose, every 8 to 12 weeks for months three to six, then every 12 weeks. (See <a href=\"topic.htm?path=general-principles-of-management-of-rheumatoid-arthritis-in-adults#H111271411\" class=\"medical medical_review\">&quot;General principles of management of rheumatoid arthritis in adults&quot;, section on 'Monitoring and prevention of drug toxicity'</a>.)</p><p>Closer monitoring is advised in patients receiving <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> (MTX) and LEF in combination. As an example, we obtain a CBC, creatinine, albumin, and transaminases every two to four weeks for the first three months (or following a dose increase), every four weeks for the next three months, then every three months subsequently. Some experts prefer that patients receiving MTX and LEF concurrently be monitored monthly for at least the first year, then increase the monitoring interval to only every two months [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/54\" class=\"abstract_t\">54</a>].</p><p class=\"headingAnchor\" id=\"H3599805797\"><span class=\"h2\">Warnings and monitoring for liver disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients receiving LEF should be closely monitored for signs of liver disease. LEF can be prescribed in patients with a history of previously abnormal liver function tests (LFTs) on MTX whose values subsequently normalize but should also be closely monitored. This approach is consistent with the American College of Rheumatology (ACR) recommendations for LEF, which indicate that LEF should not be used in patients with significant prior liver disease suggestive of cirrhosis (Child-Pugh scale A or greater) but allow use in patients with prior elevated LFTs that have returned to normal [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/55\" class=\"abstract_t\">55</a>]. Patients with acute or chronic infection with hepatitis B or C, whether or not they have been treated, should not receive LEF.</p><p>The 2010 US Food and Drug Administration (FDA) warning based upon review of the cases of liver injury described above states [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/41\" class=\"abstract_t\">41</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with preexisting liver disease should not receive LEF.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with elevated liver enzymes (alanine aminotransferase [ALT] greater than two times the upper limit of normal) should not receive LEF.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Caution should be used in patients who are taking other drugs that can cause liver injury.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Liver enzymes should be monitored at least monthly for three months after starting LEF and at least quarterly thereafter.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If the ALT rises to greater than two times the upper limit of normal while the patient is on LEF, LEF should be stopped, <a href=\"topic.htm?path=cholestyramine-resin-drug-information\" class=\"drug drug_general\">cholestyramine</a> washout should be begun to speed the removal of LEF from the body, and follow-up LFTs should be conducted at least weekly until the ALT value is within normal range.</p><p/><p>These FDA recommendations for monitoring frequency are consistent with those of the 2008 ACR recommendations on the use of LEF in rheumatoid arthritis (RA) as well as subsequent ACR guidelines [<a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/55,56\" class=\"abstract_t\">55,56</a>].</p><p class=\"headingAnchor\" id=\"H4252372094\"><span class=\"h2\">Patients receiving vitamin K antagonists</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients taking <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> and related agents, the international normalized ratio (INR) should be more carefully monitored after initiation of LEF because concomitant use of the drugs may affect the INR in either direction. (See <a href=\"#H2803875512\" class=\"local\">'Drug metabolism and drug interactions'</a> above and <a href=\"topic.htm?path=warfarin-and-other-vkas-dosing-and-adverse-effects\" class=\"medical medical_review\">&quot;Warfarin and other VKAs: Dosing and adverse effects&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">CONTRAINDICATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=leflunomide-drug-information\" class=\"drug drug_general\">Leflunomide</a> (LEF) is contraindicated in pregnant and nursing women and in patients with preexisting liver disease. Live vaccines should not be administered to patients being treated with LEF. (See <a href=\"#H1257958\" class=\"local\">'Pregnancy and lactation'</a> below and <a href=\"#H5\" class=\"local\">'Adverse effects'</a> above.)</p><p class=\"headingAnchor\" id=\"H1257958\"><span class=\"h1\">PREGNANCY AND LACTATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Women of reproductive potential should not receive therapy until pregnancy has been excluded, they have been counseled concerning fetal risk, and reliable contraceptive measures have been confirmed. Following treatment, pregnancy should be avoided until undetectable serum concentrations (&lt;0.02 <span class=\"nowrap\">mg/L)</span> are verified.</p><p>Despite the prolonged half-life of the active metabolite, the drug and its metabolites can be relatively rapidly removed from the body by one of several measures, most commonly use of <a href=\"topic.htm?path=cholestyramine-resin-drug-information\" class=\"drug drug_general\">cholestyramine</a> treatment. (See <a href=\"#H1540158001\" class=\"local\">'Treatment to accelerate drug elimination'</a> above.)</p><p>The risks of <a href=\"topic.htm?path=leflunomide-drug-information\" class=\"drug drug_general\">leflunomide</a> (LEF) use during conception, pregnancy, and lactation are reviewed in detail separately. (See <a href=\"topic.htm?path=safety-of-antiinflammatory-and-immunosuppressive-drugs-in-rheumatic-diseases-during-pregnancy-and-lactation#H19\" class=\"medical medical_review\">&quot;Safety of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation&quot;, section on 'Leflunomide'</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=rheumatoid-arthritis-symptoms-and-diagnosis-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)&quot;</a> and <a href=\"topic.htm?path=rheumatoid-arthritis-treatment-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Rheumatoid arthritis treatment (Beyond the Basics)&quot;</a> and <a href=\"topic.htm?path=disease-modifying-antirheumatic-drugs-dmards-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H24\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=leflunomide-drug-information\" class=\"drug drug_general\">Leflunomide</a> (LEF) achieves its antiinflammatory effects through the inhibition of a mitochondrial enzyme termed dihydroorotate dehydrogenase (DHODH), leading to a decrease in the synthesis of ribonucleotide uridine monophosphate pyrimidine (rUMP). (See <a href=\"#H2\" class=\"local\">'Mode of action'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A starting dose of 20 <span class=\"nowrap\">mg/day</span> of LEF is appropriate for most patients for whom LEF therapy is indicated. Some experts but not others use a loading dose. (See <a href=\"#H3\" class=\"local\">'Pharmacokinetics and drug elimination'</a> above and <a href=\"#H2124266280\" class=\"local\">'Role of loading dose'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>LEF has a side effect profile comparable with that of <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> (MTX). The most common adverse effects, those related to the gastrointestinal tract, are minimized if no loading dose is used. (See <a href=\"#H3\" class=\"local\">'Pharmacokinetics and drug elimination'</a> above and <a href=\"#H5\" class=\"local\">'Adverse effects'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We advise monthly monitoring of liver function tests (LFTs) for the first three months of therapy, followed by testing at least every three months when LEF is used as a single agent. In patients who receive LEF in combination with MTX, liver function should be monitored more closely (eg, monthly for at least the first six to twelve months). (See <a href=\"#H3691082048\" class=\"local\">'Monitoring'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/1\" class=\"nounderline abstract_t\">Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000; 59:841.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/2\" class=\"nounderline abstract_t\">Fox RI, Herrmann ML, Frangou CG, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 1999; 93:198.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/3\" class=\"nounderline abstract_t\">Panek JJ, Jezierska A, Mierzwicki K, et al. Molecular modeling study of leflunomide and its active metabolite analogues. J Chem Inf Model 2005; 45:39.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/4\" class=\"nounderline abstract_t\">Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159:2542.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/5\" class=\"nounderline abstract_t\">Fox RI. Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol Suppl 1998; 53:20.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/6\" class=\"nounderline abstract_t\">Liu S, Neidhardt EA, Grossman TH, et al. Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents. Structure 2000; 8:25.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/7\" class=\"nounderline abstract_t\">Xu X, Blinder L, Shen J, et al. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice. J Immunol 1997; 159:167.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/8\" class=\"nounderline abstract_t\">Dimitrijevic M, Bartlett RR. Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of mononuclear cells in rheumatoid arthritis. Transplant Proc 1996; 28:3086.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/9\" class=\"nounderline abstract_t\">Grisar J, Aringer M, K&ouml;ller MD, et al. Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cells. Ann Rheum Dis 2004; 63:1632.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/10\" class=\"nounderline abstract_t\">Salmi M, Rajala P, Jalkanen S. Homing of mucosal leukocytes to joints. Distinct endothelial ligands in synovium mediate leukocyte-subtype specific adhesion. J Clin Invest 1997; 99:2165.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/11\" class=\"nounderline abstract_t\">Kraan MC, de Koster BM, Elferink JG, et al. Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients. Arthritis Rheum 2000; 43:1488.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/12\" class=\"nounderline abstract_t\">Kim JY, Yang MS, Oh CD, et al. Signalling pathway leading to an activation of mitogen-activated protein kinase by stimulating M3 muscarinic receptor. Biochem J 1999; 337 ( Pt 2):275.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/13\" class=\"nounderline abstract_t\">Kim KA, Kim S, Chang I, et al. IFN gamma/TNF alpha synergism in MHC class II induction: effect of nicotinamide on MHC class II expression but not on islet-cell apoptosis. Diabetologia 2002; 45:385.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/14\" class=\"nounderline abstract_t\">Kim PH, Kagnoff MF. Transforming growth factor beta 1 increases IgA isotype switching at the clonal level. J Immunol 1990; 145:3773.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/15\" class=\"nounderline abstract_t\">Zhang X, Brunner T, Carter L, et al. Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med 1997; 185:1837.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/16\" class=\"nounderline abstract_t\">Kraan MC, Reece RJ, Barg EC, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum 2000; 43:1820.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/17\" class=\"nounderline abstract_t\">Sharp JT, Strand V, Leung H, et al. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000; 43:495.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/18\" class=\"nounderline abstract_t\">Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol 1999; 162:2095.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/19\" class=\"nounderline abstract_t\">Siemasko K, Chong AS, J&auml;ck HM, et al. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol 1998; 160:1581.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/20\" class=\"nounderline abstract_t\">Shaw J, Chen B, Wooley P, et al. A novel leflunomide analog, UTL-5b (GBL-5b), suppresses JAK3, MAP3K2, and LITAF genes. Am J Biomed Sci 2011; 3:218.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/21\" class=\"nounderline abstract_t\">Burger D, Begu&eacute;-Pastor N, Benavent S, et al. The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes. Rheumatology (Oxford) 2003; 42:89.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/22\" class=\"nounderline abstract_t\">Gilbert C, Levasseur S, Desaulniers P, et al. Chemotactic factor-induced recruitment and activation of Tec family kinases in human neutrophils. II. Effects of LFM-A13, a specific Btk inhibitor. J Immunol 2003; 170:5235.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/23\" class=\"nounderline abstract_t\">Stuhlmeier KM. Effects of leflunomide on hyaluronan synthases (HAS): NF-kappa B-independent suppression of IL-1-induced HAS1 transcription by leflunomide. J Immunol 2005; 174:7376.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/24\" class=\"nounderline abstract_t\">Vergne-Salle P, L&eacute;ger DY, Bertin P, et al. Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes. Cytokine 2005; 31:335.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/25\" class=\"nounderline abstract_t\">Elkayam O, Yaron I, Shirazi I, et al. Active leflunomide metabolite inhibits interleukin 1beta, tumour necrosis factor alpha, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures. Ann Rheum Dis 2003; 62:440.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/26\" class=\"nounderline abstract_t\">Cao WW, Kao PN, Aoki Y, et al. A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-beta 1, and suppression of the immunostimulatory cytokine, IL-2. Transplant Proc 1996; 28:3079.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/27\" class=\"nounderline abstract_t\">Dziedziejko V, Kurzawski M, Safranow K, et al. The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide. Pharmacogenomics 2011; 12:41.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/28\" class=\"nounderline abstract_t\">Hopkins AM, Wiese MD, Proudman SM, et al. Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis. Br J Clin Pharmacol 2016; 81:113.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/29\" class=\"nounderline abstract_t\">Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 2002; 41:421.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/30\" class=\"nounderline abstract_t\">Prakash A, Jarvis B. Leflunomide: a review of its use in active rheumatoid arthritis. Drugs 1999; 58:1137.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/31\" class=\"nounderline abstract_t\">Chonlahan J, Halloran MA, Hammonds A. Leflunomide and warfarin interaction: case report and review of the literature. Pharmacotherapy 2006; 26:868.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/32\" class=\"nounderline abstract_t\">Lim V, Pande I. Leflunomide can potentiate the anticoagulant effect of warfarin. BMJ 2002; 325:1333.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/33\" class=\"nounderline abstract_t\">Kirchheiner J, Brockm&ouml;ller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77:1.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/34\" class=\"nounderline abstract_t\">Cohen SB, Iqbal I. Leflunomide. Int J Clin Pract 2003; 57:115.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/35\" class=\"nounderline abstract_t\">Osiri M, Shea B, Robinson V, et al. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev 2003; :CD002047.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/36\" class=\"nounderline abstract_t\">Cutolo M, Bolosiu H, Perdriset G, LEADER Study Group. Efficacy and safety of leflunomide in DMARD-naive patients with early rheumatoid arthritis: comparison of a loading and a fixed-dose regimen. Rheumatology (Oxford) 2013; 52:1132.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/37\" class=\"nounderline abstract_t\">Bergner R, Peters L, Schmitt V, L&ouml;ffler C. Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study. Clin Rheumatol 2013; 32:267.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/38\" class=\"nounderline abstract_t\">Bohanec Grabar P, Rozman B, Tomsic M, et al. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur J Clin Pharmacol 2008; 64:871.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/39\" class=\"nounderline abstract_t\">Grabar PB, Rozman B, Logar D, et al. Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2009; 68:1367.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/40\" class=\"nounderline abstract_t\">van Roon EN, Jansen TL, Houtman NM, et al. Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity. Drug Saf 2004; 27:345.</a></li><li class=\"breakAll\">FDA Drug Safety Communication: New boxed warning for severe liver injury with arthritis drug Arava (leflunomide) www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm218679.htm (Accessed on July 15, 2010).</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/42\" class=\"nounderline abstract_t\">Bird P, Griffiths H, Tymms K, et al. The SMILE study -- safety of methotrexate in combination with leflunomide in rheumatoid arthritis. J Rheumatol 2013; 40:228.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/43\" class=\"nounderline abstract_t\">Curtis JR, Beukelman T, Onofrei A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis 2010; 69:43.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/44\" class=\"nounderline abstract_t\">Nurmohamed MT, van Halm VP, Dijkmans BA. Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis. Drugs 2002; 62:1599.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/45\" class=\"nounderline abstract_t\">Rozman B, Praprotnik S, Logar D, et al. Leflunomide and hypertension. Ann Rheum Dis 2002; 61:567.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/46\" class=\"nounderline abstract_t\">Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006; 54:1435.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/47\" class=\"nounderline abstract_t\">Conway R, Low C, Coughlan RJ, et al. Leflunomide Use and Risk of Lung Disease in Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis of Randomized Controlled Trials. J Rheumatol 2016; 43:855.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/48\" class=\"nounderline abstract_t\">Bharadwaj A, Haroon N. Peripheral neuropathy in patients on leflunomide. Rheumatology (Oxford) 2004; 43:934.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/49\" class=\"nounderline abstract_t\">Kho LK, Kermode AG. Leflunomide-induced peripheral neuropathy. J Clin Neurosci 2007; 14:179.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/50\" class=\"nounderline abstract_t\">Negi A, Rhys-Dillon C, Camilleri JP. A case of distal renal tubular acidosis (type 1) presenting with musculoskeletal pain. Rheumatology (Oxford) 2004; 43:809.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/51\" class=\"nounderline abstract_t\">Bonnel RA, Graham DJ. Peripheral neuropathy in patients treated with leflunomide. Clin Pharmacol Ther 2004; 75:580.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/52\" class=\"nounderline abstract_t\">Cohen JD, Jorgensen C, Sany J. Leflunomide-induced aseptic meningitis. Joint Bone Spine 2004; 71:243.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/53\" class=\"nounderline abstract_t\">Li J, Huang H, Zhang H. Detection of residual solvents in leflunomide by GC. Northwest Pharmaceutical Journal 2010; 1:003.</a></li><li class=\"breakAll\">Reports of Leflunomide Hepatotoxicity in Patients with Rheumatoid Arthritis. http://www.rheumatology.org/publications/hotline/0801leflunomide.asp (Accessed on January 10, 2013).</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/55\" class=\"nounderline abstract_t\">Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59:762.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-dosing-and-adverse-effects-of-leflunomide-in-the-treatment-of-rheumatoid-arthritis/abstract/56\" class=\"nounderline abstract_t\">Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 2016; 68:1.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 7515 Version 14.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H24\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">MODE OF ACTION</a><ul><li><a href=\"#H2501225977\" id=\"outline-link-H2501225977\">Inhibition of DHODH and rUMP synthesis</a></li><li><a href=\"#H2301183157\" id=\"outline-link-H2301183157\">Effects on immune cells and inflammation</a></li><li><a href=\"#H470404786\" id=\"outline-link-H470404786\">Genetic factors influencing effects of leflunomide</a></li></ul></li><li><a href=\"#H3\" id=\"outline-link-H3\">PHARMACOKINETICS AND DRUG ELIMINATION</a><ul><li><a href=\"#H2709062733\" id=\"outline-link-H2709062733\">Pharmacokinetics</a></li><li><a href=\"#H2803875512\" id=\"outline-link-H2803875512\">Drug metabolism and drug interactions</a></li><li><a href=\"#H1540158001\" id=\"outline-link-H1540158001\">Treatment to accelerate drug elimination</a></li></ul></li><li><a href=\"#H3746518806\" id=\"outline-link-H3746518806\">DOSING</a><ul><li><a href=\"#H2124266280\" id=\"outline-link-H2124266280\">Role of loading dose</a></li><li><a href=\"#H1339659498\" id=\"outline-link-H1339659498\">Ongoing daily dose</a></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">ADVERSE EFFECTS</a></li><li><a href=\"#H3691082048\" id=\"outline-link-H3691082048\">MONITORING</a><ul><li><a href=\"#H3681297272\" id=\"outline-link-H3681297272\">Routine laboratory monitoring</a></li><li><a href=\"#H3599805797\" id=\"outline-link-H3599805797\">Warnings and monitoring for liver disease</a></li><li><a href=\"#H4252372094\" id=\"outline-link-H4252372094\">Patients receiving vitamin K antagonists</a></li></ul></li><li><a href=\"#H15\" id=\"outline-link-H15\">CONTRAINDICATIONS</a></li><li><a href=\"#H1257958\" id=\"outline-link-H1257958\">PREGNANCY AND LACTATION</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H23\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H24\" id=\"outline-link-H24\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"RHEUM/7515|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=RHEUM/56364\" class=\"graphic graphic_figure\">- Activation of leflunomide</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=alternatives-to-methotrexate-for-the-initial-treatment-of-rheumatoid-arthritis-in-adults\" class=\"medical medical_review\">Alternatives to methotrexate for the initial treatment of rheumatoid arthritis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=disease-modifying-treatment-of-relapsing-remitting-multiple-sclerosis-in-adults\" class=\"medical medical_review\">Disease-modifying treatment of relapsing-remitting multiple sclerosis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-induced-lung-disease-in-rheumatoid-arthritis\" class=\"medical medical_review\">Drug-induced lung disease in rheumatoid arthritis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=general-principles-of-management-of-rheumatoid-arthritis-in-adults\" class=\"medical medical_review\">General principles of management of rheumatoid arthritis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-refractory-cutaneous-dermatomyositis-in-adults\" class=\"medical medical_review\">Management of refractory cutaneous dermatomyositis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-refractory-discoid-lupus-and-subacute-cutaneous-lupus\" class=\"medical medical_review\">Management of refractory discoid lupus and subacute cutaneous lupus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methotrexate-induced-lung-injury\" class=\"medical medical_review\">Methotrexate-induced lung injury</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=musculoskeletal-manifestations-of-systemic-lupus-erythematosus\" class=\"medical medical_review\">Musculoskeletal manifestations of systemic lupus erythematosus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nsaids-and-acetaminophen-effects-on-blood-pressure-and-hypertension\" class=\"medical medical_review\">NSAIDs and acetaminophen: Effects on blood pressure and hypertension</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=disease-modifying-antirheumatic-drugs-dmards-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rheumatoid-arthritis-symptoms-and-diagnosis-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rheumatoid-arthritis-treatment-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Rheumatoid arthritis treatment (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=polyarticular-juvenile-idiopathic-arthritis-treatment\" class=\"medical medical_review\">Polyarticular juvenile idiopathic arthritis: Treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=safety-of-antiinflammatory-and-immunosuppressive-drugs-in-rheumatic-diseases-during-pregnancy-and-lactation\" class=\"medical medical_review\">Safety of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-psoriatic-arthritis\" class=\"medical medical_review\">Treatment of psoriatic arthritis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-rheumatoid-arthritis-in-adults-resistant-to-initial-biologic-dmard-therapy\" class=\"medical medical_review\">Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-rheumatoid-arthritis-in-adults-resistant-to-initial-nonbiologic-dmard-therapy\" class=\"medical medical_review\">Treatment of rheumatoid arthritis in adults resistant to initial nonbiologic DMARD therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=warfarin-and-other-vkas-dosing-and-adverse-effects\" class=\"medical medical_review\">Warfarin and other VKAs: Dosing and adverse effects</a></li></ul></div></div>","javascript":null}